Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Novo Nordisk ADR (NYSE: NVO) closed the day trading at $56.98 up 2.76% from the previous closing price of $55.45. In other words, the price has increased by $2.76 from its previous closing price. On the day, 17.85 million shares were traded. NVO stock price reached its highest trading level at $57.51 during the session, while it also had its lowest trading level at $56.64.
Ratios:
For a better understanding of NVO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 64.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.21. For the most recent quarter (mrq), Quick Ratio is recorded 0.56 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.52.
HSBC Securities Downgraded its Buy to Hold on July 31, 2025, while the target price for the stock was maintained at $57.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 246973530112 and an Enterprise Value of 333520633856. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.70, and their Forward P/E ratio for the next fiscal year is 13.53. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.22 while its Price-to-Book (P/B) ratio in mrq is 9.57. Its current Enterprise Value per Revenue stands at 1.069 whereas that against EBITDA is 2.094.
Stock Price History:
The Beta on a monthly basis for NVO is 0.64, which has changed by -0.57886183 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $139.74, while it has fallen to a 52-week low of $45.05. The 50-Day Moving Average of the stock is -9.44%, while the 200-Day Moving Average is calculated to be -26.87%.
Shares Statistics:
Over the past 3-months, NVO traded about 15.07M shares per day on average, while over the past 10 days, NVO traded about 18007920 shares per day. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.01% of the company’s shares, while institutions hold 9.35% stake in the company. Shares short for NVO as of 1753920000 were 20756474 with a Short Ratio of 1.38, compared to 1751241600 on 25701254. Therefore, it implies a Short% of Shares Outstanding of 20756474 and a Short% of Float of 0.62.
Dividends & Splits
NVO’s forward annual dividend rate is 1.73, up from 11.65 a year ago. Against a Trailing Annual Dividend Yield of 0.21009918The stock’s 5-year Average Dividend Yield is 1.49. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-03-31 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
The market rating of Novo Nordisk ADR (NVO) is currently shaped by the ongoing analysis conducted by 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $6.03, with high estimates of $6.49 and low estimates of $5.69.
Analysts are recommending an EPS of between $25.9 and $23.81 for the fiscal current year, implying an average EPS of $24.84. EPS for the following year is $25.52, with 3.0 analysts recommending between $25.89 and $25.16.
Revenue Estimates
9 analysts predict $77.65B in revenue for the current quarter. It ranges from a high estimate of $85.77B to a low estimate of $74.03B. As of the current estimate, Novo Nordisk ADR’s year-ago sales were $71.31BFor the next quarter, 9 analysts are estimating revenue of $84.05B. There is a high estimate of $99.99B for the next quarter, whereas the lowest estimate is $79.59B.
A total of 21 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $353.05B, while the lowest revenue estimate was $309.51B, resulting in an average revenue estimate of $319.85B. In the same quarter a year ago, actual revenue was $290.4BBased on 21 analysts’ estimates, the company’s revenue will be $347.15B in the next fiscal year. The high estimate is $405.13B and the low estimate is $317.52B.
